期刊文献+

重组人生长激素治疗对特发性矮小儿童的糖脂代谢及甲状腺功能的影响 被引量:14

Effects of r-h GH replacement therapy on glucose and lipid metabolism and thyroid function in children with idiopathic short stature
原文传递
导出
摘要 目的探讨重组人生长激素(r-h GH)对特发性矮小(ISS)儿童的糖、脂代谢及甲状腺功能的影响。方法选取2009年1月至2013年1月应用r-h GH治疗并定期随访的ISS儿童47例,年龄为10±3岁,治疗期限为3~24个月,随访间隔为每3个月1次,检测治疗后0~1年及治疗后1~2年时的空腹血糖、胰岛素、血脂、甲状腺功能等指标的变化。结果 r-h GH治疗后,患儿空腹血糖、胰岛素水平、胰岛素敏感指数、空腹血糖/胰岛素比值(FGIR)与治疗前比较差异无统计学意义,但FGIR有下降趋势;FGIR〈7(提示胰岛素抵抗)的患儿治疗前为13%(6/47),治疗后1~2年为18%(4/22)。治疗后动脉粥样硬化指数较前下降,而总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白水平及BMI与治疗前比较差异无统计学意义。治疗前后甲状腺功能无明显变化。结论 r-h GH治疗ISS儿童是安全可靠的,可改善脂代谢,对甲状腺功能、空腹血糖、胰岛素水平无明显影响,但有胰岛素敏感性降低的可能。 Objective To study the effects of recombinant human growth hormone (r-hGH) replacement therapy on glucose and lipid metabolism and thyroid function in children with idiopathic short stature (ISS). Methods Forty- seven ISS children with a mean age of 10±3 years treated between January 2009 and January 2013 were enrolled. All children underwent r-hGH replacement therapy for 3-24 months and were followed up once every 3 months. Fasting blood glucose (FBG), insulin (INS), blood lipids and thyroid function were measured before treatment and after 0-1 and 1-2 years of treatment. Results After treatment with r-hGH, there were no significant changes in FBG, INS, insulin sensitivity index (ISI), and FBG/INS ratio (FGIR), but the FGIR showed a declining trend. The percentage of patients with FGIR〈7 (a marker of insulin resistance) was 13% before treatment compared to 18% 1-2 years after treatment. The atherosclerosis index decreased after r-hGH treatment, but there were no significant changes in total cholesterol, triglyceride, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and BMI. Furthermore, no significant change in thyroid function was observed after r-hGH therapy. Conclusions r-hGH therapy can improve lipid metabolism, without significant impacts on thyroid function, FBG and INS. It seems to be a safe and reliable therapy for children with ISS. However, this therapy possibly reduces insulin sensitivity.
出处 《中国当代儿科杂志》 CAS CSCD 北大核心 2014年第12期1236-1240,共5页 Chinese Journal of Contemporary Pediatrics
关键词 重组人生长激素 特发性矮小 糖代谢 脂代谢 甲状腺功能 儿童 Recombinant human growth hormone Idiopathic short stature Glucose metabolism Lipid metabolism Thyroid function Child
  • 相关文献

参考文献14

  • 1Kemp SF, Frindik JP. Emerging options in growth hormone therapy: an update[J]. Drug Des Devel Ther, 2011, 5(1): 411- 419.
  • 2肖靖,田慧,李春霖,钟雯雯,孙般若,李昱芃,方福生,韩晓菲,刘永泉,成晓玲.高胰岛素血症与正常胰岛素血症糖耐量低减人群转归差异的探讨[J].中华内科杂志,2012,51(4):299-303. 被引量:7
  • 3Frindik JP, Kemp SF. Managing idiopathic short stature: role of somatropin (rDNA origin) for injection[J]. Biologics, 2010, 4(1): 147-155.
  • 4Harvey S. Extrapituitary growth hormone[J]. Endocrine, 2010, 38(3): 335-359.
  • 5Gotherstrom G, Bengtsson BA, Sunnerhagen KS, et al. The effects of five-year growth hormone replacement therapy on muscle strength in elderly hypopituitary patients[J]. Clin Endocrinol (Oxf), 2005, 62(1): 105-113.
  • 6Burgert TS, Vuguin PM, Dimartino-Nardi J, et al. Assessing insulin resistance: application of a fasting glucose to insulin ratio in growth hormone-treated children[J]. Horm Res, 2002, 57(1-2): 37-42.
  • 7Quigley CA, Gill AM, Crowe B J, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature[J]. J Clin Endocrinol Metab, 2005, 90(9): 5188-5196.
  • 8Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment[J]. Lancet, 2000, 355(9204): 610-613.
  • 9Lebrtm P, Van Obberghen E. SOCS proteins causing trouble in insulin action[J]. Acta Physiol (Oxf), 2008, 192(1): 29-36.
  • 10Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia[J]. Eur J Endocrinol, 2007, 157(6): 695-700.

二级参考文献26

  • 1傅春江,王旭开,杨成明,王红勇,方玉强,石伟彬.重组生长激素对兔血脂及肝脏LDL受体mRNA的影响[J].第三军医大学学报,2005,27(8):753-755. 被引量:9
  • 2Boguszewski CL, Meister LH, Zaninelli DC, et al. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults[J]. Endocrinol, 2005,152 ( 1 ) : 67.
  • 3Elgzyri T,Castenfors J,Hagg E,et al. The effects of GH replacement therapy on cardiac morphology and function, exercise capacity and serum lipids in elderly patients with GH deficiency[J]. Clin endocrinol (Oxf), 2004, 61 (1) : 113.
  • 4Wallis M. In: De I.a Cruzed. Regulation of growth hormone and somatic growth[M]. Elsever Science Publisher, 1992,2:852.
  • 5Weltman A,Despres J P,Clasey J L,et al. hnpact of abdominal visceral fat, growth hormone, fitness, and insulin on lipids and lipoproteins in older aduhs[J]. Metabolism, 2003,52(1) :73.
  • 6Fideleff H L, Boquete H,Giaccio A, et al. Medium and long-term outcome of growth hormone therapy in growth hormone deficient adults[J]. Medicina(B Aires),2006,66 (4) :296.
  • 7van der Klaauw A A, Romijn J A, Biermasz N R,et al. Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency[J]. Endocrinology,2006,155(5) :701.
  • 8李春霖,陆菊明,潘长玉,朱艳,王淑玉,田慧,邓心新.糖耐量低减者二年后的转归[J].中华内分泌代谢杂志,1997,13(2):81-89. 被引量:82
  • 9田慧,方福生,邵迎红,李春霖,李剑,曹秀堂,闫双通,钟文雯,李妍妍,孙静芳,潘长玉,陆菊明,窦京涛,马芳玲,邹效漫,白香成,马琴,王惠先,王钰.腰围、体重指数和高胰岛素血症在代谢综合征评估中的意义[J].解放军医学杂志,2007,32(10):1001-1004. 被引量:27
  • 10Clark A,Jones LC,de Koning E. Decreased insulin secretion in type 2 diabetes:a problem of cellular mass or function[J].Diabetes,2001,(Suppl 1):S169-171.

共引文献8

同被引文献111

引证文献14

二级引证文献96

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部